Cantor Fitzgerald Issues Positive Estimate for NBIX Earnings

Key Points

• Cantor Fitzgerald increased its FY2025 earnings per share estimate for Neurocrine Biosciences from $4.39 to $4.50, surpassing the current consensus estimate of $4.28.
• Several analysts have given Neurocrine a buy rating, with price targets ranging from $141.00 to $174.00.
• Neurocrine's recent earnings report revealed a 16.5% year-over-year revenue increase, with earnings per share exceeding analyst expectations at $1.06.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Neurocrine Biosciences in a research report issued on Thursday, July 31st. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of $4.50 for the year, up from their previous estimate of $4.39. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

A number of other research analysts have also recently issued reports on NBIX. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Wall Street Zen raised shares of Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Saturday. HC Wainwright lowered their price target on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. UBS Group lifted their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a research report on Wednesday, July 9th. Finally, Wedbush lifted their price target on shares of Neurocrine Biosciences from $137.00 to $141.00 and gave the company an "outperform" rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of "Moderate Buy" and a consensus target price of $160.90.

Neurocrine Biosciences Stock Up 0.5%

Shares of NASDAQ:NBIX traded up $0.68 on Friday, hitting $128.91. The company had a trading volume of 1,395,006 shares, compared to its average volume of 901,206. The firm's 50-day simple moving average is $128.26 and its two-hundred day simple moving average is $120.88. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $157.40. The firm has a market capitalization of $12.79 billion, a price-to-earnings ratio of 38.14, a P/E/G ratio of 1.32 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm had revenue of $687.50 million during the quarter, compared to analysts' expectations of $653.09 million. During the same period last year, the company posted $1.63 EPS. The company's quarterly revenue was up 16.5% compared to the same quarter last year.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Huntington National Bank boosted its position in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after buying an additional 97 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. GeoWealth Management LLC raised its stake in Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares during the last quarter. WPG Advisers LLC acquired a new position in Neurocrine Biosciences in the 1st quarter valued at about $32,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Neurocrine Biosciences in the 1st quarter valued at about $34,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Kevin Charles Gorman sold 9,613 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total value of $1,157,212.94. Following the transaction, the director directly owned 514,596 shares in the company, valued at $61,947,066.48. This trade represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jude Onyia sold 59,819 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the sale, the insider owned 18,289 shares of the company's stock, valued at $2,385,982.94. This trade represents a 76.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,251 shares of company stock valued at $14,978,602. Corporate insiders own 4.80% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.